News and Announcements
Read the latest news from the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. The links below take you to articles where you can learn more about our center's latest events and accomplishments.
“Breast cancer, particularly early-stage breast cancer, is a front-loaded illness from a resource expenditure standpoint,” said William Gradishar, MD, Robert H. Lurie Comprehensive Cancer Center of Northwestern University. Dr. Gradishar is Chair of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Panel for Breast Cancer.
On October 23, Barbara and Bruce Jacobson, co-founders of Campaign 2 Save Lives (C2SL), presented Jessica Altman, MD, and Olga Frankfurt, MD, co-directors of the Lurie Cancer Center’s Leukemia Transactional Research Program (LTRP) with a check for $30,000 to further their leukemia research, treatment, and care.
Robert H. Lurie Comprehensive Cancer Center of Northwestern University has been awarded a $4.1 million five-year U54 grant from the National Cancer Institute (NCI) to establish a consortium, conducted as a partnership with the Mayo Clinic School of Medicine in the U.S., and the University of Lagos and University of Jos in Nigeria.
- Lou Malnati Cancer Research Foundation Makes Landmark Donation to Northwestern Brain Tumor Institute11.13.2017
The Lou Malnati Cancer Research Foundation has made a transformational donation to the Northwestern Brain Tumor Institute (NBTI) to help advance medical education, collaborate on research initiatives and create innovative clinical models of care for patients with brain and spinal cord tumors. NBTI is a nationally recognized leader in the fight against brain and spinal cord tumors, offering patients the most advanced clinical trials and treatment options available.
Nanotechnology and neurology come together in the fight against a deadly brain cancer. The blood-brain barrier, which keeps potentially diseased blood from reaching the brain, is nearly impenetrable. So when Alexander Stegh, neurology and medicine, saw his lab’s preliminary 2013 results on breaching the barrier, he was understandably intrigued.
Massimo Cristofanilli, MD, professor of medicine, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, discusses overcoming resistance to endocrine therapy in ER+ breast cancer.
For the first time, researchers control cells’ chromatin to prevent cancer from adapting to treatment
Patients with advanced neuroendocrine tumors had a similar quality of life while on a newly approved chemotherapy drug, as compared to patients receiving a placebo, according to a Northwestern Medicine study.
It’s aggressive and deadly, and unfortunately, glioblastoma is the most common malignant brain tumor in adults. John McCain was recently diagnosed. Ted Kennedy died from the lethal tumor. But now, an early human clinical trial — the culmination of decades of work — shows a glimmer of hope.
Members of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University joined together on Friday, Oct. 27 at a retreat to highlight achievements in Lurie Cancer Center’s research programs.
More than 600 guests joined the Hippocratic Cancer Research Foundation (HCRF) on October 14 at the Hilton Chicago. Chaired by founder Eleni Bousis, HCRF’s Gala, “The Wings to Cure,” raised more than $600,000 to fund groundbreaking research at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
A team of scientists has identified the genetic drivers of diffuse large B-cell lymphoma, the most common type of blood cancer, and determined the genes’ clinical significance.
Small RNA molecules can trigger a mechanism hidden in every cell, forcing it to commit suicide, according to a new Northwestern Medicine study, the first to identify molecules that trigger such a fail-safe mechanism.
Maha H. Hussain, MD is interviewed by Clinical Advances in Hematology & Oncology about genomics and the potential applications of genomics in patients with cancer.
Two fifth-year doctoral students in Northwestern University Feinberg School of Medicine’s Walter S. and Lucienne Driskill Graduate Program in Life Sciences (DGP) were awarded highly prestigious Fellowships from the National Cancer Institute (NCI). Ryan Rickels and Christie Sze received grants for research conducted in the lab of Ali Shilatifard, the Robert Francis Furchgott Professor, Chairman of the Department of Biochemistry and Molecular Genetics, and a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
Elizabeth Thomas Bartom, PhD, Assistant Professor of Biochemistry and Molecular Genetics, has received a Research Specialist Award (R50) from the National Cancer Institute (NCI). Granted for the first time in 2016, the program was introduced to encourage exceptional scientists who want to pursue research within the context of an existing NCI-funded basic, translational, clinical or population science cancer research program, working in collaboration with other scientists.
Women with invasive breast cancer who were treated with an aggressive lymph node removal saw no survival benefit compared to those who received a less invasive procedure, according to a new clinical trial.
The Lurie Cancer Center paid tribute to Chung Lee, PhD, Professor Emeritus in the Department of Urology at Northwestern University Feinberg School of Medicine.
A new Northwestern Medicine study reveals surprising findings about an enzyme called Set1A and its function in embryonic stem cell self-renewal and differentiation.
A Blog Post by Chuck Maniscalco | Sept. 21, 2017
During Blood Cancer Awareness Month, MPN Research Foundation announces the beginning of a multi-center project to identify new targets for treating patients with myeloproliferative neoplasms (MPNs), a group of progressive blood cancers.
A comprehensive genomic analysis of the most common kidney cancer in children – found genetic mutations involving two distinct processes, potentially providing new opportunities for future treatments.
Northwestern Medicine research has explained the mechanism behind ‘pauses’ in transcription, which has implications for future cancer therapies.
Feinberg — and the University more broadly — is increasingly focused on ensuring that exciting discoveries made by basic scientists are also soon turned into treatments that impact human health.
Over the past 30 years, squamous cell carcinoma of the anus (SCCA) is one of the few cancers with steadily rising incidence in the United States, with the most rapid increase seen in black men. To further investigate this trend, researchers at the University of Texas Southwestern Medical Center looked at more than 7,800 cases of SCCA in the United States and found that the complex chemistry of social, economic, biologic, and cultural factors led not only to disparities in incidence, but also survival.
Northwestern Medicine scientists and engineers have invented a range of bioactive “tissue papers” made of materials derived from organs that are thin and flexible enough to even fold into an origami bird. The new biomaterials can potentially be used to support natural hormone production in young cancer patients and aid wound healing.
Joshua Meeks, MD, PhD, was awarded a 2017 SWOG Early Exploration & Development award from the Hope Foundation SEED Fund.
Leo I. Gordon, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses novel immunomodulatory agents and standard treatment options for patients with relapsed or refractory Hodgkin lymphoma.
For women facing a cancer diagnosis, there are countless questions that come to mind. From treatments and medications to the emotional journey of living with cancer, it’s easy for the mind to get full — and fast. The last question a woman is likely to ask, however, is an important one: What about my bones?
Dr. Shira Dinner is one of 10 investigators nationwide to receive a 2017 Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute (NCI).
At this year’s event, over $714,000 was raised for basic science cancer research at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
There are a number of treatment methods being explored to treat glioblastoma.
Scientists used a new approach to identify a promising therapeutic target for glioblastoma, which was previously overlooked in traditional approaches.
Members of The Lynn Sage Foundation gathered to celebrate another year of high-impact support for cancer research at the Lurie Cancer Center.
Patients with melanoma that has spread to the sentinel nodes did not see any survival benefit after a surgical procedure called immediate completion lymph node dissection, according to a study in the New England Journal of Medicine.
A protein called POP2 inhibits a key inflammatory pathway, calming the body’s inflammatory response before it can become destructive, Northwestern Medicine scientists have demonstrated in mouse models.
The rising cost of targeted oral anticancer medications may put a substantial financial burden on individual patients enrolled in Medicare’s prescription drug benefit program, Part D, according to a new study.
Early phase Northwestern Medicine research has demonstrated a potential new therapeutic strategy for treating glioblastoma.
Design can control color, intensity of light by varying cavity architecture
Northwestern Medicine scientists have demonstrated that an enzyme called IDH1 plays a significant role in cancer progression and may be a target for novel drug therapies.
A new study finds that patients with double-hit lymphoma who received autologous stem cell transplantation saw no survival benefit, compared to patients who did not undergo the procedure.
Ride for 3 Reasons is dedicated to heart—cancer research, ALS research and palliative care.
Sarki A. Abdulkadir, MD, PhD, Co-Director of Global Health and head of the Leadership Program of the Specialized Programs of Research Excellence in Prostate Cancer at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and John T. Grayhack, MD, Professor of Urological Research at Northwestern University Feinberg School of Medicine, was honored today at the Celebrating 21 Years of the CURE Program Recognition Ceremony (the “Recognition Ceremony”) for his achievements through the Continuing Umbrella of Research Experiences (CURE) program, an initiative of the National Cancer Institute (NCI), part of the National Institutes of Health (NIH).
A Blog Post by Chuck Maniscalco | June 22, 2017
A cancer drug for certain types of leukemia and lymphoma can also prevent reactions to some of the most common airborne allergies, according to a recent Northwestern Medicine study.
Students formed the group Stop Breast Cancer Now to raise awareness and funds for breast cancer research at the Lurie Cancer Center.
The Harold E. Eisenberg Foundation announced a commitment of $1.5 million to establish the Harold E. Eisenberg Foundation GI Cancer OncoSET Program at the Lurie Cancer Center.
The walk raised $3.1 million to accelerate breast cancer research; improve access to screening, diagnosis and treatment; and educate people about breast cancer.
An investigational neural stem cell therapy that works with a common cold virus to seek out and attack malignant glioma is being tested at Northwestern Medicine in a phase I clinical trial.
Younger men with prostate cancer had a decreased risk of cancer progression while under active surveillance, compared to men older than 60, according to a recent study.
New investigational drug acts like a cancer-seeking missile in brain.
This year’s fundraiser raised over $600,000 in support of the NBTI’s mission areas of research, education and care.
Targeted cancer treatment might treat food allergies, too.
Read a Q-and-A with Jasmine May, a fifth-year student in the Medical Scientist Training Program, who studies the pathophysiology of glioblastoma.
Bioprosthetic ovaries produced mouse pups in otherwise infertile mice.
On May 15, faculty presented a panel discussion on advances in melanoma detection and treatment to supporters and friends of Northwestern Medicine.
The first drug using spherical nucleic acids to be systemically given to humans has been developed by Northwestern University scientists and approved by the Food and Drug Administration as an investigational new drug for an early-stage clinical trial in the deadly brain cancer glioblastoma multiforme.
It's been approved by the Food and Drug Administration as an investigational new drug for an early-stage clinical trial in the deadly brain cancer glioblastoma multiforme.
A Blog Post by Chuck Maniscalco | May 11, 2017
A study published in Cancer Cell revealed the mechanism by which a gene fusion called ETO2-GLIS2 promotes the development of an aggressive form of acute megakaryoblastic leukemia.
This generous gift will support sarcoma investigations and care being conducted by Mark Agulnik, MD.
A combination of ultrasound and cystoscopy is the most cost-effective approach to detecting cancer in patients who show microscopic amounts of blood in their urine, according to a JAMA Internal Medicine study.
A Blog Post by Chuck Maniscalco | May 1, 2017
The symposium provided healthcare professionals with cutting-edge information on significant advances in precision medicine and the evolving standard of personalized cancer care.
A study sheds new light on the molecular foundations of human acral lentiginous melanoma, a rare sun-shielded melanoma.
We combine our world-leading nanotechnology research with cutting-edge medical applications to make a difference in people’s lives.
Dancing With Chicago Celebrities celebrated the success of their “Rock Around the Clock”-themed event at a recent reception.
OncoSET, the flagship clinical and research program of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, combines oncology with genomic sequencing to provide cutting-edge cancer care personalized for each patient.
Women who underwent autologous breast reconstruction following a mastectomy reported greater psychosocial and sexual well-being than those who chose implant-based reconstruction, according to a study published in the Journal of Clinical Oncology.
Targeting a molecule called B7-H4 may lead to the development of new therapies that boost the immune system’s ability to fight cancer, according to a review published in the journal Immunological Reviews.
Northwestern Medicine scientists have developed a novel testing platform to assess, in real time, the efficacy of nanomaterials in regulating gene expression.
Northwestern medicine scientist have shown how a medical device that delivers alternating electrical fields in addition to traditional chemotherapy can improve survival for patients with glioblastoma.
Read Dr. Cristofanilli's interview with CancerNetwork on prognostic markers for breast cancer.
Dr. Stupp talks about tumor-treating fields for brain tumors.
The Prostate Cancer Foundation profiles trailblazing scientist Maha Hussain, MD.
Miniature, personalized reproductive system will test drugs for safety, effectiveness in women.
A Blog Post by Chuck Maniscalco | March 28, 2017
Scientists have demonstrated that a small-molecule inhibitor can preserve fertility in mice, when administered as a co-treatment with conventional chemotherapy.
Two senior leaders of the Lurie Cancer Center, Jeffrey Wayne, MD, and William Gradishar, MD, have added new leadership positions at Northwestern Medicine.
A new study defined the architecture of nuclear lamins, the fibrous proteins in a cell’s nucleus, providing further insights into their role in cell structure.
Dr. Gradishar describes the NCCN Clinical Practice Guidelines process.
Learn more about how Dr. Hussain is driving clinical advances in prostate and bladder cancer.
From the lab to the hospital, Northwestern University’s collaborative community of researchers fosters innovation and potentially-lifesaving breakthroughs.
A Northwestern Medicine study has established a new safety index for a common group of chemotherapy drugs, by using a stem cell model to screen such therapies for cardiotoxicity.
The Robert H. Lurie Comprehensive Cancer Center of Northwestern University is pleased to announce the four recipients of the 2017 Liz and Eric Lefkofsky Innovation Research Awards.
A. Vania Apkarian and Seema Khan are both Lurie Cancer Center members.
In research published in Nature Medicine, Northwestern Medicine scientists have found a molecule that stops the growth of an aggressive pediatric brain tumor for which there is no current treatment.
A phase 1 clinical trial of venetoclax and rituximab combination therapy was shown to be an effective chemo-free treatment option for patients with difficult-to-treat chronic lymphocytic leukemia.
A newly identified biomarker may predict treatment response in patients with chronic myelogenous leukemia, according to a Northwestern Medicine study.
In recent Northwestern Medicine clinical trials, an experimental drug improved survival rates for patients with advanced midgut neuroendocrine tumors compared to a standard therapy.
A paper published in Molecular Cell provides new insight into a protein complex called COMPASS and its function during histone methylation, a key modification that regulates gene expression.
A powerful Northwestern University imaging tool is the first to measure the structure of isolated chromosomes without the use of fluorescent labels.
Chicago Health explores cancer survivorship.
Cancer initiative spurs research—and already advancements are happening.
Northwestern physician joins panel that makes evidence-based recommendations on clinical preventive services.
A surgical procedure called a pelvic exenteration may be curative for more than half of women with a form of advanced cervical cancer who have failed other treatments.
A KevinMD blog post from Dr. Shikha Jain.
Northwestern Medicine scientists have identified the unique targets of two enzymes that activate ubiquitination, a key modification of proteins that controls a variety of cellular processes.
A novel national trial for people with no established alternative to treat their rare cancers is being co-led by Northwestern Medicine investigators, who helped conceive of and develop the project.
The addition of the drug cetuximab to standard chemoradiation reduced the incidence of relapse for patients with anal cancer, but was associated with significant adverse effects, according to recent Northwestern Medicine clinical trials.
Northwestern is offering a national trial of immune therapies for patients who have run out of options.
A recent clinical trial assessed the efficacy and safety of the drug ibrutinib in patients with Waldenstrom’s macroglobulineaemia, a type of non-Hodgkin lymphoma, who were not responding to other treatments.
Chad A. Mirkin is director of the International Institute for Nanotechnology at Northwestern University.
The cancer center's statement supports fewer vaccinations, urges action to increase national vaccination rates.
Northwestern Medicine scientists have identified a molecular therapy to prevent the growth of a rare pediatric leukemia.
A recent study explores the use of metabolic markers to target ovarian cancer stem cells and could improve outcomes of existing therapies.
William J. Gradishar weighed in for this Cancer Today article.
Northwestern neurosurgeons have developed a new surgical method to determine how much brain tumor to remove.
Chicago Magazine writes about an implanted device that Northwestern doctors are using to treat breast cancer.
Northwestern's Cancer Survivorship Institute addresses the medical, psychological and social challenges patients face after their cancer is gone.
Dr. Jessica Altman talks about whether there is such thing as treatment-free remission for a CML patient.
Fellows are nominated by their peers for outstanding contributions to innovation.
Generalizable approach could enable the construction of biosensors for a wide range of metabolites.
Trained partners take the embarrassment out of stripping down for irregular mole checks.
Northwestern University synthetic biologists have developed a general method for “rewiring” immune cells to help overcome immunosuppression in cancer.
Northwestern University synthetic biologists now have developed a general method for “rewiring” immune cells.
The foundation raises funds for the Lurie Cancer Center’s Translational Bridge Program.
Dr. Massimo Cristofanilli weighs in on the unique challenges of triple-negative breast cancer.
Read a patient's story about her breast cancer treatment plan.
Together, Abbvie and the Lurie Cancer Center will work in several areas of oncology research
A new strategy for targeting a protein called GRP78 could be used to simultaneously provide diagnostic imaging and deliver treatment for inflammatory breast cancer, according to a recent study.